NTEK Nothing else matters!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have a position in NFLX so I'll post here. It requires some DD to see what is taking place in this sector and NFLX has yet to show a profit but I'm willing to wait as with the other content provider as well. Both have lots of potential.
Not real 4k ? Are you kidding me, please explain the differences in Netflix and UltraFlix technology. Both are building a customer base worldwide which is one of the reasons dilution was used to get very good quality content on UF. Pay attention.
Thanks Simps, Well said because eventually BIEL'S technology can't be held back. Proof is in use and I have and this product changed how I think about pain treatment. Others here simply have an agenda possibly because big pharma has always feared the loss of revenue feeding millions upon millions pain pills! It's as disgusting as those who bash this board (they know who they are) possibly working for these companies to keep ActiPatch from market. Hmmmm as always desperate in their comments, I smell fear!
Great post , perfect for 2016! This is our year to become a stores shelf product in the U.S. ! DD finally paying off!
Merry Christmas is right, the long slow road to rise is BIELs finally. Though the PPS is yet to follow all the hard work is amazing and showing signs to payoff. Thank you BIEL!
Everything is turning 4K and if Netflix doesn't get on board with it soon (16 movies) UltraFlix (already over 1,000 + 4K) will eat their lunch!
Just a matter of time, not if but when. BIEL products work that's a fact, I have used this product for years, it's a winner. Fact.
No doubt ! Disruption is putting it lightly, this deal adds up to the cost of my subscription of Netflix for a year! Hate to say it but I won't be adding to my position here for awhile when I can add to this for a lot more upward potential!
http://slickdeals.net/f/8311161-ultraflix-4k-uhd-black-friday-rental-deal-99-for-99-25-for-49-99-or-10-for-24-99?utm_source=android_app
I'm afraid that's already happening, May have to shrink my position here and move some of it to this......
http://legitimatepennystocks.com/this-small-company-may-be-netflixs-fall-from-grace/#more-60
ctronics Chairman Letter to Shareholders
[22-October-2015]
FREDERICK, Md., Oct. 22, 2015 /PRNewswire/ -- The following is a letter from the Chairman of BioElectronics Corporation (OTC Pink: BIEL) to shareholders:
Dear Biel Shareholders:
This has been a busy last few months that has resulted in some very positive news for BIEL shareholders and I want to take a few minutes to put these events in perspective.
It has been about three years since Andrew Whelan and the BioElectronics management team put together and communicated to you our four strategic initiatives which were:
Execute an aggressive marketing and sales program in large European markets and select other global markets; Develop political and public support to compel the US FDA to recognize our therapeutic solution to provide an alternative to the devastating side effects and addictions of OTC and prescription drugs; Continue high quality clinical research to further substantiate clinical efficacy and establish more indications of use; and, Lower our cost of capital to finance expansion.
Let me briefly discuss each of these.
As a Marketing Professor at the Fuqua School of Business at Duke University, I continually tell my students that launching a new product is never an easy task. For BIEL the hurdle was particularly high. Not only are we a small firm with constrained resources and limited access to working capital, but our product had almost no brand awareness or market acceptance. At that time our distributors in Europe were working through the medical profession to establish some limited distribution. Although this approach was working to some extent, we decided that we needed to take a new, bold approach and try to market our product ourselves and to do this through over the counter (OTC) channels. This led us to look for one or more retail chains that would carry our product. Just about two years ago we were able to get limited distribution in Boots UK Limited, the largest and most well-known pharmacy chain in the UK. Our next task was to generate sales even though we had no brand awareness and Boots was not willing to aggressively market ActiPatch®. This coupled with the fact that our prior marketing research indicated that consumers were skeptical of the efficacy of our product and thus were not likely to buy it just because they saw it on the retail shelf, told us that we had a tough road ahead unless we came up with a creative approach. Our challenge, then, was to show Boots and the world that our product would sell and we needed to do this by first making consumers aware of the benefits of our innovative product and then getting them to try it and spread the word about its efficacy. And we had to do this with a limited marketing budget. Clearly this was a daunting task, but one that I am happy to report was executed successfully.
Our approach was unique and innovative. We first settled on targeting chronic pain sufferers versus going after those with acute pain. Next, we used a combination of public relations, Boots customer reviews, charities websites, and social media to generate some initial buzz about our product. However, the key marketing initiative was to offer potential customers a trial product that lasted seven days at a price of about $5. We knew that if the pain sufferer tried the product for this amount of time that a clear majority would find substantial and sustained relief. We started this sampling program about 15 months ago and since then we have sold over 80,000 7-day trial devices. Another major benefit of obtaining these trial users has been the establishment of a massive email data base allowing us to survey them and in the process gain substantial amounts of data about how much ActiPatch® impacts their baseline pain, how they use ActiPatch®, how likely it is to improve their quality of life, and their purchase and repurchase behavior of our commercially available 720-hour product at the retailer's regular price. The net of all this is that we can show retailers that by offering "skeptical" potential buyers the option of buying the 7-day trial product initially, the majority of triers find clinically significant pain relief and consequently will continue to buy the 720 hour product for years to come. Current estimates are that use of a 7-day trial product will result in about 50-60% of the triers purchasing the 720 hour retail ActiPatch® and over the next year these users will purchase another 2-3 devices. Thus, the life-time value of this newly acquired customer is substantial. We continue to track the sampling and the resulting sales and feel confident that this innovative marketing approach will continue to result in ever growing sales volumes.
Due to the success of this approach Boots positioned ActiPatch® more prominently in their stores and nearly doubled the number of their pharmacy's carrying ActiPatch®. Not surprisingly ActiPatch® is currently their largest selling analgesic on their website. Building on this achievement, we just received an order from the second largest retail chain in the UK, Lloyds Pharmacy Limited, to stock 1,077 of their outlets and another one from Gordon Chemists who have over 60 outlets. In addition, we have received several inquiries from other retail chains who are looking to stock and sell ActiPatch® in their stores. The bottom line of all this is that we have found an economical way of launching our product into new markets and it is gratifying to see the resulting positive customer response after they try our product. This is because for the first time there is a solution available to them that enables the majority of the chronic pain sufferers to get substantial and sustained pain relief with no adverse side effects. All this leads to strong brand loyalty, great word of mouth promotion and multiple repeat purchases. It also means that these chronic pain suffers are able to improve the quality of their lives and decrease their use in systemic analgesic pain medications, including reductions in opioid-based analgesics.
Given this success we are now leveraging our newly gained experience in other markets. Thus, in Canada we have recently launched the sale of ActiPatch® through a distributor using the same "Try and Tell" program and this distributor is finding similar success. We expect to have some very large sales coming soon. More info will be announced when the ink dries on the purchase orders.
Needless to say, a marketing campaign is only as good as the product that is being marketed. The market is telling us that ActiPatch® is a great product. It represents a paradigm shift in pain management behavior. It is clear from our customer survey data that the majority of chronic pain sufferers are getting lasting relief. The net result is a strong and loyal customer base that will continue to grow over time. We see this approach of getting trial and then preference as the backbone of being able to successfully launch our product not only in the UK, but also in numerous other countries.
With respect to point 2, we previously put out a brief press release noting that last week's announcement from the FDA was very good news for BIEL. The U.S. Food and Drug Administration's final rule 890.5290 on nonthermal pulsed shortwave devices will assist our efforts to win clearance to market over-the-counter in the US as it is already allowed in the majority of countries around the world. I expect that the good clinical data resulting from our third strategic intitiative, continuing high quality clinical research, coupled with our strong consumer survey data and the hard work by our management and legal team will push that ball over the goal line and allow us to finally win OTC clearance in the US for ActiPatch® Therapy.
Results of our clinical studies have continued to be very positive and are generating more interest in trying our technology on new indications. We will have more to say on this at a later date.
I wish I could report substantial gains on our fourth strategic initiative, i.e., to reduce the cost of capital. We had hoped to have more success in building interest in funding our ongoing work. With this noted as our sales results continue to improve we believe we have a more complete and compelling story. We continue to seek substantial partners either though equity or distribution agreements.
We are poised to move out of the development stage with this company and fulfill its potential as we change the way people heal and successfully manage their chronic pain. I thank you for your continued support.
Richard Staelin
Chairman of the Board
BioElectronics
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-chairman-letter-to-shareholders-300164082.html
SOURCE BioElectronics Corporation
Who sent this? Needs to be vetted otherwise not valid!
Awesome news , BIEL is headed for some real attention just a matter of time!
Oops forgot one little detail! ActiPatch now falls in a catagory of FDA approval! My how things have changed the course of the river! Let the flooding begin as in retail U.S. $$$$$$$!!!!!
Yes sir blowin the dust off my 2009 shares slickin them up what has been long awaited by those who now what they own. Great times ahead ! The reality REALLY IS setting in! Congrats to all longs no matter how long you have been witnessing a pardigm shift pain treatment!
Your fact is NOT fact simply. I state fact and proof of my own DD the gizmo you try to deny actually works and my results of use simply puts all that you ever continue to post here as self interest of no value on this board. THAT'S A FACT!
Yes I agree, how silly to call it a scam when Apple is working with them on content cuz we all know Apple loves to work with scam companies as does Samsung, Sony, Hisense and Vizio LOL! My concerns are more with Netflix and when they will turn a profit.
No I'm not comparing, Netflix UltraFlix completely different subscription models. Not Sure when Netflix will show a profit? UltraFlix will be profitable etimate 2nd qtr. 2016. Doesn't sound like a scam to me. Fact how penny stocks hold share holder meetings? I rest my case.
I disagree with you, audited financials is not important as building the business and its a race for content and UltraFlix is winning hands down. For the record the Paramount deal was inked Sept. 21 last month nothing had been promised until then that's a fact. Movies right now like Interstellar, Rocky, Star Trek the Movie and other in the series, Forest Gump, Transformers just for starts. I have wanted that on NFLX but nothing comes close to what is desirable to watch. Netflix has a total of 13 4K movies WOW, Not trying to take anything away from NFLX they have established the standard but little tech companies can move so much quicker the large behemoths and UltraFlix is on every major TV manufactures 4K TV this coming Christmas. Don't need luck just perseverance and what I see happening is taking place right under NFLX's nose. Go to any Best Buy, Target, Walmart, Sears and see who's app emblem is next to Netflix's on the 4k TV advertisements. Actually its front and center Just sayin!
Its a shame some here just don't do their DD before making statements. The company has had to use dilution as a means to get ahead of the curve and put "quality content" on board. Can NFLX say they have a contract to put 950 Paramount movies on their platform? The answer is NO and while I like NFLX the content has a lot to be desired! Have you looked at the management that has come together at that other company? Most are have been very heavy hitters at other companies making huge contributions to make those companies what they are today. Names like Redbox, Roku, Nintendo, Sega, Sony to name a few. Far from a scam my friend I have visited the headquarters several times in the last few years and become more and more impressed with what is taking place. NFLX has had its place and still does but they have huge hurdles to become profitable and yet projected revs for that other company by end of 2016 is 70 mill. No I think quite the opposite and is why I am closing some of my position here. As the market has become shaky so has NFLX in its pursuit of 4K content.
I am a long time fan of Netflix and you said:
Has anyone tried Hulu and Amazon Prime streaming videos? I have. No comparison. Don't believe the media hype.
Content is not there and it's 1/3 of Netflix selection.
Competition is good. But this should not effect Netflix stock price. So Apple is jumping in now with original content. Has anyone watched the Netflix original content. Tough act to follow. I'm not worried.
No pumping just stating facts, watch n learn. ; )
No pumping just stating facts, watch n learn. ; )
JohnSamuel I totally agree right now it is hard to compare the two especially from a PPS standpoint The only comparison to point out is the difference in technology that NTEK has over NFLX, Amazon Prime and any other content provider. See the link and compare quality of the pictures.
Content is the key. Once the 250-500 A list movies is loaded on UltraFlix it's game on.
https://www.flickr.com/gp/134209578@N08/C2N4Je
Netflix is a different subscriber model where it might not align well with what UltraFlix model is. The A list content movies (over 500) about to be uploaded to Ultraflix would what will set them ahead of all 4K content providers including Netflix. The other piece of it is the streaming technology is used at UltraFix/4K studios is stand alone right now. NanoTech takes content, and creates multiple resolutions, multiple bit rates, and now multiple encoding methods (h.264 and h.265) and stores those files at its data center in Fremont, CA. NanoTech's streaming channels, which operate on many different end user devices, including phones, tablets, and set top boxes have the playback software which contacts the server for a piece of content. The codec is not sent to the machine, it's preinstalled in the machine. Updates to codecs may be transmitted down the TV or player via software updates (in their systems done automatically and without user interaction needed). When the request is made for a piece of content, information is passed up to the server including geographic location, playback device capabilities, and line speed and quality information. The servers then determine the closest edge network connection and the content is delivered via the edge caching servers to the player or TV with the Ultraflix app. They said it best "We didn't invent streaming, we merely are doing unique implementations of streaming using our own software".
Love Netflix but the new competition on the block is UltraFlix. Streaming at 4MB lossless 4K puts NetFlix way behind in the content race worldwide especially since many countries such as India have a ways to go in the internet infrastructure speeds. Dedicated to entirely 4K content the future is UltraFlix!
ultraflix.com
ntek.com
UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan
Topics will Include UK Progress and New Clinical Publications
PR Newswire
FREDERICK, Md., Aug. 3, 2015
FREDERICK, Md., Aug. 3, 2015 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), maker of consumer medical electronics products for pain management, announced that Andrew J. Whelan, President will be interviewed by Stu Taylor on his program "On Business" at 9am EDT on Wednesday, August 5th. To listen to the interview live, tune to:
http://tunein.com/radio/Money-Matters-Boston-1120-s27548/
Mr. Whelan is expected to report on the exceptional acceptance the company's flagship product, ActiPatch Therapy, is achieving in the UK. Other topics for discussion include upcoming clinical publications and the status of its US FDA market clearance progress.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
About Stu Taylor
Stu Taylor's "On Business" Program airs on Radio America Network & Biz Talk Radio Network Stu Taylor is the nationally syndicated business radio talk show host of Equity Strategies, and the host of Boston morning drive with Stu Taylor on Business.
Contact:
BioElectronics
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
Stu Taylor
Brittney Lewellen
Media Relations
Direct Line: 602-441-3474
blewellen@upticknewswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uptick-news-wire-radio-show-will-interview-bioelectronics-ceo-andrew-whelan-300122233.html
SOURCE BioElectronics Corporation
Good post I think you hit the nail on the head. I'll admit I'm way way down in the red but haven't lost sight nor sold because this will turn in time with the right announcement. Laying low but actively watching .......THAT'S ME !
It's called business 101, don't set expectations without setbacks, delays, modifications. I'm not wrong and your not right, growing something from nothing to something takes a lot more time then most think. Few understand what it takes. Do DD and vaidate what you know, talk to the source if you can. Sorry it's the way business works YOU DO YOUR OWN NETWORKING!
It's called patience, it's key here, it WILL happen!
Have you seen the pinball machine in person, live action? It is the game changer , the future of NTGL is looking very bright!
I'm buying more, NTGL is huge right!
I hate when I have to eat my words!
Agree I had faith in this until it went dark. Something isn't adding up her and the company better blog today with an update not filled with excuses!
Don't dispute it AL STONE is the CEO of NTGL end of story. In fact I will be meeting AL in Vegas later this summer and I will give a full report.
Ditnit that's a great link but no mention of pinball 2047 in it. BETTER DD please!
Link please to the 2013 Expo demonstrating your statement.
You are exactly right and they will be accounted for. HVELD soon to be NTEG will be first online completed audits with SB9 passing and being signed within two weeks.
Your are right ! Thus looks like we been duped!